Homeopathic company looking for participants for non-interventional study

Dear members of the Faculty of Homeopathy,

The Germancompany PharmaFGP is currently preparing a non-interventional study in the UK for eight homeopathic human medicinal products that have been granted a marketing authorization in Germany and Austria. For these eight products the company plans to apply for marketing authorizations of homeopathic medicinal products in accordance with UK Product Licenses of Right (PLRs).

Therefore, PharmaFGP is looking for UK homeopathic practitioners interested in participating in a non-interventional studyby using the products for the proposed indications and recording the outcome.

Requirements for participation:

In order to support their knowledge of homeopathy, the practitioner should have been awarded the MFhom/FFhom and be a member of the Faculty of Homeopathy or be a member of other recognised UK homeopathic organisations. A copy of the practitioners Curriculum Vitae should be provided.

Expense allowance:

Participating practitioners will receive an expense allowance of 100 GBP per fully recorded case of use.

Set-up of the study:

The participating practitioners are requested to use the products in patients in the proposed indications and to record the details of use as well as the outcome of the therapy.

The following products will be tested in the study:

Product name / Homeopathic ingredients / Dosage form / Uses
RubaX / Rhus toxicodendron, D6 / Oral drops / Rheumatic pain and cramp.
Joint and muscular pain and stiffness including backache, sciatica, lumbago, fibrositis
RubaX MONO / Rhus toxicodendron, D6 / Tablets / Rheumatic pain and cramp.
Joint and muscular pain and stiffness including backache, sciatica, lumbago, fibrositis
Deseo / Turnera diffusa, D4 / Oral drops / Sexual disorders such as erectile dysfunction and loss of libido.
Neradin / Turnera diffusa, D4 / Tablets / Sexual disorders such as erectile dysfunction and loss of libido.
Taumea / Anamirta cocculus, D4
Gelsemium sempervirens, D5 / Oral drops / Improvement of symptoms of vertigo.
Restaxil / Cimicifuga racemose, D2
Cyclamen purpurascens, D3
Gelsemium sempervirens, D2
Iris versicolor, D2
Spigelia anthelmia, D2 / Tablets / Neuralgia
Sedacalman / Avena sativa, Ø
Humulus lupulus, Ø
Hypericum perforatum, D1
Kalium bromatum, D2
Matricaria recutita, Ø
Valeriana officinalis, Ø / Tablets / Agitation, anxiety, irritability, nervous tension, stresses, strains and tenseness
Difficulties falling asleep.
Neodolor LQ / Cimicifuga racemose, D2
Cyclamen purpurascens, D3
Gelsemium sempervirens, D2
Iris versicolor, D2
Spigelia anthelmia, D2 / Oral drops / Headache including migrainous headache.

At the end of the study, the participating homeopathic practitionersare requested to provide a statement on headed notepaper testifying that they have used the product for the proposed indications including the following information:

  • use of the product in the proposed indications
  • age group that product has been used in
  • how long the product has been used for and frequency of use
  • any adverse reactions observed
  • if the product is used in his/her practice or if he/she was approached by the applicant to trial the product in their practice and record the outcome.

Contact:

Interested practitioners are kindly requested to contact PharmaFGP directly.

Mr. Bastian Baasch, tel: +49-89-7879790-47, ,